

IMPACT FACTOR 2.8





an Open Access Journal by MDPI

# Non-coding RNAs in Alzheimer's Disease

Guest Editor:

#### Dr. Evgenia Salta

Laboratory of Neurogenesis & Neurodegeneration, Netherlands Institute for Neuroscience, 1105 Amsterdam, The Netherlands

Deadline for manuscript submissions:

closed (20 November 2021)

## Message from the Guest Editor

Alzheimer's disease (AD) was until recently perceived as a neuron-centric disorder with linearly evolving pathology. Novel molecular and genetic insights have challenged the unidirectional linearity of the pathogenic cascade in AD and underscored the significance of intertwined complex cellular pathways, gene networks, and feed-forward regulatory loops that may differentially impact distinct pathogenic endophenotypes and cellular phases of the disease. Mapping the mechanistic heterogeneity and multifactorial nature of AD is a key challenge, given the current lack of effective disease-modifying therapies.

The emerging complexity of the transcriptional landscape poses great challenges to our conventional preconceptions of how the genome regulates brain function and dysfunction. Non-protein-coding RNAs (ncRNAs) confer a high level of intricate and dynamic regulation of various molecular processes in the central nervous system and have been widely implicated in Alzheimer's disease pathophysiology. Understanding these events may help to develop novel diagnostic and therapeutic strategies.













an Open Access Journal by MDPI

### **Editor-in-Chief**

## Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

## Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

#### **Contact Us**